This is a study that invites adults with Crohn's disease and have been responding well to
Adalimumab (Humira ®) for at least 6 months. Patients frequently discontinue maintenance
medications in Crohn's disease, particularly when in remission. Patients want to know that
they truly need to take a medication, yet they don't want to have flares. The purpose of this
study is to see that if we monitor the patient, along with looking at changes in their stool
samples, we can safely stop the maintenance medication Adalimumab for up to 48 weeks, or add
as-needed dosing only, and keep them in remission.